uniQure Presents New Preclinical Data in SCA3, Fabry Disease, and Hemophilia A at the ASGCT Annual Meeting
May 14, 2020 07:00 ET
|
uniQure Inc.
~ Substantial Presence with 22 Data Presentations Highlighting Breadth of Research, Technology and Manufacturing Platform ~ ~ New Non-Human Primate Data Demonstrate Feasibility of...
uniQure Announces First Quarter 2020 Financial Results and Highlights Recent Company Progress
April 29, 2020 07:00 ET
|
uniQure Inc.
~ Completed Target Patient Dosing in Phase III HOPE-B Trial of Etranacogene Dezaparvovec in Hemophilia B ~ ~ Announced 22 Presentations at Upcoming ASGCT Virtual Annual Meeting ~ LEXINGTON, Mass....
New Report Demonstrates Potential for Cell and Gene Therapies to Provide Cost Savings
January 10, 2020 11:23 ET
|
Alliance for Regenerative Medicine
WASHINGTON, D.C., Jan. 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the cell and gene...
Eric Dostie Memorial College Scholarship Now Accepting 2020 Applicants
December 17, 2019 18:37 ET
|
FFF Enterprises.com
TEMECULA, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Nufactor®, a specialty infusion company and subsidiary of FFF Enterprises, Inc., is now accepting applications for the Eric Dostie Memorial...
Option Care Health Selected by Highmark as Preferred Provider of Hemophilia Treatment
November 19, 2019 14:14 ET
|
Option Care Health, Inc.
BANNOCKBURN, Ill., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Option Care Health, Inc., the nation’s largest independent provider of home and alternate treatment site infusion therapy services, has been...
uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting
November 06, 2019 09:16 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 06, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy
November 05, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 05, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec
October 31, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences
July 26, 2019 07:00 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 26, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
July 06, 2019 07:00 ET
|
uniQure Inc.
~ FIX Activity Up to 54% of Normal, with Mean of 45% of Normal, at 36 WeeksAfter Administration of AMT-061 in Phase IIb Study ~ ~ Clinical Benefit and Tolerability of AMT-060 Maintained in All...